Uses of Hepatymo 300mg

Hepatymo 300mg has the active ingredient tenofovir disoproxil. Tenofovir's action is to inhibit viral polymerase (reverse transcriptase) by direct competition with natural substrates. The article will provide readers with some information about the uses, dosage and notes when using Hepatymo 300 mg.

Hepatymo 300mg has the main ingredient tenofovir disoproxil. For the treatment of chronic hepatitis B in adult patients with compensated liver disease, evidence of viral replication and histological evidence of active inflammation or fibrosis, or in association with other antiretroviral drugs in the treatment of HIV . Tenofovir disoproxil fumarate is a helical nucleotide diester similar to adenosine monophosphate, which is a prodrug of tenofovir. After being phosphorylated to the active diphosphate form, tenofovir diphosphate is resistant to HBV polymerase and HIV reverse transcriptase.
Tenofovir disoproxil fumarate is rapidly absorbed and converted to tenofovir after oral administration, peaking in 1-2 hours. Bioavailability is increased when the drug is taken with a high-fat meal. The drug is widely distributed throughout the body tissues, especially the kidneys and liver.

Hepatymo 300mg is used orally with the following dosage:
Treatment of HIV
The recommended treatment dose is 1 tablet x 1 time/day and in combination with other antiretroviral drugs.
Prophylaxis of HIV infection:
The recommended prophylactic dose is 1 tablet x 1 time/day in combination with other antiretroviral drugs. Prophylactic treatment should begin as soon as possible after exposure (preferably within hours rather than days) and continue for the next 4 weeks if tolerated.
Treatment of chronic hepatitis B:
The recommended dose for chronic hepatitis B treatment is 1 tablet x 1 time/day for more than 48 weeks.
Patients with renal impairment
Dose reduction in patients with renal impairment is required by adjusting the dosing interval based on the patient's creatinine clearance (CrCl):
CrCl >50ml/min: Use usual dose at frequency 1 time/day. CrCl 30 to 49ml/min: Take doses every 48 hours. CrCl 10 to 29ml/min: Take every 72 to 96 hours. Hemodialysis patients: Take each dose of Hepatymo 7 days apart or 12 hours after dialysis. Patients with hepatic impairment
No dose adjustment of hepatymo is necessary in patients with hepatic impairment.

Symptoms of hepatymo overdose include skin rash, nausea, vomiting, decreased blood phosphate levels, acute renal failure, and lactic acidosis. Management of hepatymo overdose is symptomatic and supportive. Hemodialysis can be used to remove tenofovir.

> 10%:
Central nervous system: Insomnia, headache, pain, dizziness, depression Dermatology: Skin rash (including maculopapular rash, pustules, vesicles, pruritus or urticaria) Internal Secretion and metabolism: Hypercholesterolemia, increased serum triglycerides Gastrointestinal: Abdominal pain, nausea, vomiting, diarrhea Neuromuscular and skeletal: Decreased bone mineral density, increased creatine phosphokinase, asthenia Other: Fever 1 to 10 %:
Cardiovascular: Chest pain Central nervous system: Fatigue, anxiety, peripheral neuropathy Endocrine and metabolic: Weight loss, urinary tract, hyperglycemia, lipodystrophy Digestive: Increased blood amylase Serum, anorexia, dyspepsia, flatulence Genitourinary system: Hematuria Hematology and cancer: Neutropenia Liver: Increase in serum ALT, increase in serum AST, increase in serum alkaline phosphatase Neuromuscular and skeletal: Back pain, joint pain, muscle pain Kidney: Increased serum creatinine, kidney failure Respiratory: Sinusitis, upper respiratory tract infection, nasopharyngitis, pneumonia Instructions for handling ADR
If experiencing side effects of the drug c, the patient needs to stop using the drug and notify the doctor or go to the nearest medical facility for timely treatment.

Contraindicated to use Hepatymo 300mg in case the patient is sensitive to tenofovir or any of its ingredients. Serum ALT and HBV DNA levels should be monitored after discontinuation of hepatymo therapy. Discontinue hepatymo if lactic acidosis, severe hepatomegaly, steatosis, and after treatment for severe hepatitis. Hepatymo should not be used in patients with galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Decrease in bone mineral density: In clinical trials, the use of the drug was associated with a decrease in bone mineral density in both adults and pediatric patients. In all clinical trials in children, skeletal growth (height) did not appear to be affected. The long-term effects on bone health and future fracture risk in adult and pediatric patients are unknown. Consider monitoring bone density in adult and pediatric patients with a history of pathological fractures or other risk factors for bone loss or osteoporosis. Consider calcium and vitamin D supplementation for all patients. Chronic Hepatitis B: Severe exacerbations of hepatitis B can occur when the drug is stopped. Monitor liver function for several months after stopping treatment and may have to restart hepatitis B therapy as needed. Acute exacerbations of hepatitis B following treatment may lead to hepatic decompensation and liver failure, particularly in patients with advanced liver disease or cirrhosis. Treatment of HBV in undetected or untreated HIV patients can lead to drug-resistant HIV. Patients should therefore be tested for HIV status before starting treatment. Hepatic Impairment: Caution is advised when administering Hepatymo to patients with impaired liver function. Limited data support the treatment of chronic hepatitis B in patients with decompensated liver disease, but an increased incidence of adverse events, including renal dysfunction, has been observed. Renal impairment: Use with caution in patients with renal impairment and dosage adjustment is required. IDSA guidelines recommend avoiding tenofovir in HIV patients with pre-existing renal disease (CrCl <50 mL/min and not on hemodialysis or GFR <60 mL/min/1.73 m2) when other therapies are available. another effective HIV treatment because data suggest an increased risk of chronic kidney disease (CKD). Ability to drive and use machines: No data are available in this regard. Usually hepatymo will not affect the ability to drive and use machines. Pregnancy: The drug has the potential to cross the placenta. There are not enough studies to verify safety in pregnant women, so only use hepatymo when absolutely necessary and exactly as prescribed by your doctor. Lactation: Tenofovir is present in breast milk. The American Association for the Study of Liver Disease (AASLD) chronic hepatitis B guidelines do not consider antiretroviral therapy to be a contraindication to breast-feeding in hepatitis B patients who are not co-infected with HIV. Antiviral drugs are minimally excreted in human milk and do not cause significant toxicity. However, because data are limited and the risk is unknown when infants are exposed to low levels, the manufacturer recommends against breastfeeding while the mother is taking the drug. Drug interactions: Tenofovir disoproxil fumarate should not be combined with the following drugs Didanosine, atazanavir, tacrolimus and drugs that reduce or compete for renal elimination. Patients coinfected with HIV/HBV should combine antiretroviral drugs and an appropriate diet. In summary, hepatymo is an antiviral drug used in the treatment of chronic hepatitis B and in combination with other antiretroviral agents in the treatment of HIV. Patients need to strictly follow the doctor's instructions and dosage to ensure safety and effectiveness when using the drug.
Vinmec International General Hospital is one of the hospitals that not only ensures professional quality with a team of leading medical professionals, modern equipment and technology, but also stands out for its examination and consultation services. comprehensive and professional medical consultation and treatment; civilized, polite, safe and sterile medical examination and treatment space.